Noa Krawczyk, PhD
NYU Langone Health, Division of Epidemiology, Center for Opioid Epidemiology and Policy, Department of Population Health - Assistant Professor
Email: noa.krawczyk@nyulangone.org
Education
PhD, Mental Health, Johns Hopkins Bloomberg School of Public HealthBA, Biology, Hunter College at the City University of New York – Macaulay Honors College
Research Interests
Substance use, Opioids, Overdose, Health services, Mental health, Criminal justice, Treatment BIO
Noa Krawczyk is an Assistant Professor in the Department of Population Health at NYU School of Medicine and a member of the Center for Opioid Epidemiology and Policy. She completed her PhD in the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health, where she studied substance use epidemiology, and previously worked as a Fulbright research scholar to study treatment and health services among cocaine users in Brazil. Her research focuses on studying ways to address barriers to evidence-based treatment for opioid use disorders and improving quality and effectiveness of care, especially among vulnerable groups such as persons with criminal justice involvement. Her work centers on bridging research and practice by collaborating with health organizations, public health and government agencies and advancing science that can help inform evidence-based policies and practices that reduce harm and promote long term recovery. Projects
Principal Investigator, Beyond Treatment Initiation: Enhancing Opioid Use Disorder Care Transitions Across Health System Touchpoints. Active
Principal Investigator, Simulating the Impact of Office-Based Methadone Prescribing and Pharmacy Dispensing on OUD Treatment and Overdose in New York State: An Agent-Based Modeling Approach. Active
Principal Investigator, Trends in Psychosis Related to Hospitalizations Among Youth Following Cannabis Legalization in Colorado. Completed
Publications
Recent
Ross RK, Nunes EV, Olfson M, Shulman M, Krawczyk N, Stuart EA, Rudolph KE (2024).
Comparative effectiveness of extended-release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients
Addiction, 119 (11), 1975-1986. doi: 10.1111/add.16630. PMCID: PMC11479822.
Comparative effectiveness of extended-release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients
Addiction, 119 (11), 1975-1986. doi: 10.1111/add.16630. PMCID: PMC11479822.
Shearer R, Hagedorn H, Englander H, Siegler T, Kibben R, Fawole A, Patten A, Fitzpatrick A, Laes J, Fernando J, Appleton N, Oot E, Titus H, Krawczyk N, Weinstein Z, McNeely J, Baukol P, Ghitza U, Gustafson D, Bart G, Bazzi A (2024).
Barriers and facilitators to implementing treatment for opioid use disorder in community hospitals
Journal of Substance Use and Addiction Treatment, 167, 209520. doi: 10.1016/j.josat.2024.209520.
Barriers and facilitators to implementing treatment for opioid use disorder in community hospitals
Journal of Substance Use and Addiction Treatment, 167, 209520. doi: 10.1016/j.josat.2024.209520.
Kline D, Hepler SA, Krawczyk N, Rivera-Aguirre A, Waller LA, Cerda M (2024).
A state-level history of opioid overdose deaths in the United States: 1999-2021
PLoS One, 19 (9), e0309938. doi: 10.1371/journal.pone.0309938. PMCID: PMC11379184.
A state-level history of opioid overdose deaths in the United States: 1999-2021
PLoS One, 19 (9), e0309938. doi: 10.1371/journal.pone.0309938. PMCID: PMC11379184.
Krawczyk N, Lim S, Cherian T, Goldfeld KS, Katyal M, Rivera BD, McDonald R, Khan M, Wiewel E, Braunstein S, Murphy SM, Jalali A, Jeng PJ, Kutscher E, Khatri UG, Rosner Z, Vail WL, MacDonald R, Lee JD (2024).
Transitions of care between jail-based medications for opioid use disorder and ongoing treatment in the community: A retrospective cohort study
Drug and Alcohol Dependence, 261, 111377. doi: 10.1016/j.drugalcdep.2024.111377.
Transitions of care between jail-based medications for opioid use disorder and ongoing treatment in the community: A retrospective cohort study
Drug and Alcohol Dependence, 261, 111377. doi: 10.1016/j.drugalcdep.2024.111377.
Englander H, Chappuy M, Krawczyk N, Bratberg J, Potee R, Jauffret-Roustide M, Rolland B (2024).
Comparing methadone policy and practice in France and the US: Implications for US policy reform
International Journal of Drug Policy, 129, 104487. doi: 10.1016/j.drugpo.2024.104487.
Comparing methadone policy and practice in France and the US: Implications for US policy reform
International Journal of Drug Policy, 129, 104487. doi: 10.1016/j.drugpo.2024.104487.
Notable
Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap
Journal of Substance Abuse Treatment, 103, 1-8. doi: 10.1016/j.jsat.2019.05.002. PMCID: PMC6612429.
Krawczyk N, Picher CE, Feder KA, Saloner B (2017).
Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine
Health Affairs, 36 (12), 2046-2053. doi: 10.1377/hlthaff.2017.0890. PMCID: PMC6035729.
Dr. Krawczyk's MyBibliography Profile
Selected Press